Clinical Trials
266 trialsAZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca
TroFuse-020
Merck Sharp & Dohme LLC
MK-3475-06B
Merck Sharp & Dohme LLC
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
A Study of BL-M07D1 Versus Physician's Choice of Chemotherapy in Patients With HER2-expressing Locally Advanced or Metastatic Biliary Tract Cancer After Platinum-containing Chemotherapy Failure
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
Inhibrx Biosciences, Inc
MK-3475-C66
Merck Sharp & Dohme LLC
A Study Comparing BL-B01D1 With Treatment of Physician's Choice in Patients With Locally Advanced or Metastatic Biliary Tract Cancer After Failure of Platinum-based Chemotherapy and PD-1/PD-L1 Monoclonal Antibody Therapy(PANKU-BTC01)
Sichuan Baili Pharmaceutical Co., Ltd.
A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies
Mirati Therapeutics Inc.
Beacon-BTC
J-Pharma Co., Ltd.
Clinical Trial of Lurbinectedin as Single-agent or in Combination With Irinotecan Versus Topotecan or Irinotecan in Patients With Relapsed Small-cell Lung Cancer (LAGOON)
PharmaMar
First-in-man Clinical Trial of CEB-01 PLGA Membrane in Recurrent or Locally Advanced Retroperitoneal Soft Tissue Sarcoma
CEBIOTEX
CANTOR
AstraZeneca
SGT-53 in Children With Recurrent or Progressive CNS Malignancies
SynerGene Therapeutics, Inc.
OrigAMI-1
Janssen Research & Development, LLC
OrigAMI-2
Janssen Research & Development, LLC
OrigAMI-3
Janssen Research & Development, LLC
A Study of ASP1570 Taken by Itself, or ASP1570 Taken Together With Either Pembrolizumab, Standard Therapies, or Both, in Adults With Solid Tumors
Astellas Pharma Inc
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
Astellas Pharma Inc
NAUTICALCRC
Pierre Fabre Medicament
RASolute 302
Revolution Medicines, Inc.
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd.
A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI
R-Pharm
MOONRAY-01
Eli Lilly and Company
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
Sichuan Baili Pharmaceutical Co., Ltd.
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
MOMA Therapeutics
A Study of ASP3082 in Adults With Advanced Solid Tumors
Astellas Pharma Inc
A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma
Eli Lilly and Company
Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors
Taiho Oncology, Inc.
A Study Comparing BL-M05D1 With the Investigator's Choice of Treatment Regimen in Patients With Claudin (CLDN)18.2-Positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma (GC/GEJC) Who Have Received Prior First-Line Treatment
Sichuan Baili Pharmaceutical Co., Ltd.
9-ING-41 in Patients With Advanced Cancers
Actuate Therapeutics Inc.
Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Novartis
CAMPFIRE
Eli Lilly and Company
Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
Novartis
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
Artios Pharma Ltd
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
Multitude Therapeutics Inc.
A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer
Astellas Pharma Inc
A Phase Ib/II Clinical Study on AK112 Combined or Not Combined With AK119 in pMMR/MSS Colorectal Cancer
Akeso
AK112 and Chemotherapy in First-line Metastatic Colorectal Cancer
Akeso
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
TroFuse-015
Merck Sharp & Dohme LLC
innovaTV 301
Seagen Inc.
TRIPP-FFX
OncoSil Medical Limited
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
AstraZeneca
LPM6690176 in Combination With Chemotherapy and Bevacizumab in Metastatic Colorectal Cancer Patients With RAS Mutation
Luye Pharma Group Ltd.
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors
FBD Biologics Limited
Dose-finding Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of SNB-101(SN-38) in Patients With Tumors
SN BioScience